恶性心包积液38例治疗分析  

Treatment analysis of 38 malignant pericardial effusion cases

作　　者：韩玥[1] 于雷[1] 吴晓明[1] 刘姗[1] 杨敏[1] 朱继庆[1] 

机构地区：[1]中国医学科学院肿瘤医院综合科,北京100021

出　　处：《陕西医学杂志》2011年第6期711-713,共3页Shaanxi Medical Journal

摘　　要：目的:观察心包穿刺持续引流并心包灌注治疗恶性心包积液的疗效和安全性。方法:38例恶性心包积液患者均接受了全身化疗及心包穿刺置管持续引流,其中15例心包灌注白介素-2,13例心包灌注化疗药,10例未行心包灌注。结果:白介素-2组的有效率与化疗药组相当,均优于未灌注组,且白介素-2组及未灌注组不良反应的发生率,特别是Ⅲ、Ⅳ度骨髓抑制的发生率较化疗药组低。结论:心包穿刺持续引流并心包灌注白介素-2治疗恶性心包积液疗效好、副反应少、安全性高。Objective：To observe the effect and security of continued pericardial drainage and pericardial infusion in treatment of malignant pericardial effusion.Methods：38 malignant pericardial effusion patients all accepted systemic chemotherapy and continued pericardial drainage,in which 15 patients were infused IL-2 into their pericardial cavities（IL-2 Group）,13 patients were infused chemotherapy into their pericardial cavities（Chemotherapy Group）,10 patients didn＇t accept pericardial infusion（Control Group）.Results：The effects of IL-2 Group and Chemotherapy Group were almost the same,better than those in Control Group.Adverse reactions especially Degree III/IV bone marrow depression of IL-2 Group and Control Group were less than those in Chemotherapy Group.Conclusion：Treatment of malignant pericardial effusion with continuous pericardial drainage and infusion of IL-2 into the pericardial cavity has better effects,less adverse reactions and higher securities.

关 键 词：心包积液/治疗 心包穿刺术/方法 化学疗法 肿瘤 局部灌注/方法 

分 类 号：R730.53[医药卫生—肿瘤]